Savant HWP Inc. has developed selective antagonists of the nicotinic acetylcholine receptor alpha(3)beta(4) it believes could treat a wide variety of addiction disorders because the compounds hit a pathway that underlies most pleasure-seeking behaviors, including substance abuse and over-eating.

Most approaches to addiction seek to block the effects of a single addictive substance -- for example, low-dose nicotinic receptor agonists to treat nicotine addiction and opioid receptor antagonists to treat opiate addiction.